IDH3A and metastatic neoplasm: There were seven patients in the study who received small-molecule inhibitors (SMIs), such as tyrosine kinase inhibitors (TKIs), mammalian target of rapamycin (mTOR) inhibitors, and isocitrate dehydrogenase (IDH) inhibitors, for the treatment of metastatic disease.